Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHNQOG)

• Drug Name: Zafirlukast Drug Info
• Synonyms: Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1]

• Therapeutic Class: Antiasthmatic Agents
• Cross-matching ID:
  PubChem CID: 5717
  ChEBI ID: CHEBI:10100
  CAS Number: CAS 107753-78-6
  TTD Drug ID: DMHNQOG
  VARIDT Drug ID: DR00872
  INTEDE Drug ID: DR1723
  ACDINA Drug ID: D00737

Molecule-Related Drug Atlas

Drug(s) Targeting Leukotriene CysLT1 receptor (CYSLTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Montelukast	DMD157S	Allergic asthma	CA23.0	Approved	[12]
Pranlukast	DMYHDCA	Allergic rhinitis	CA08.0	Approved	[13]
Cinalukast	DMFIC0M	Asthma	CA23	Approved	[14]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[15]
BAY-X-7195	DM2XE80	Asthma	CA23	Phase 2	[16]
Masilukast	DMDTI0L	Asthma	CA23	Phase 2	[17]
LM-1507.NA	DMW6VA0	Asthma	CA23	Phase 2	[18]
Iralukast	DMQ3RWN	Asthma	CA23	Phase 2	[19]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[20]
CR-3465	DMT7L30	Allergy	4A80-4A85	Phase 1	[17]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[21]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[22]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[25]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[27]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[28]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[22]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[6]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[30]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[31]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[32]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[33]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[34]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[30]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[35]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[36]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[11]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[52]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[11]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[52]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[53]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[11]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[11]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[54]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[55]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[56]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[31]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[41]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[42]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[43]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[44]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[46]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[47]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[48]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[49]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[50]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[48]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[51]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[49]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[48]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]

Drug(s) Metabolized By Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[6]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[6]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[6]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[6]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[6]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[6]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[6]

Drug(s) Affected By Cysteinyl leukotriene receptor 1 (CYSLTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pranlukast	DMYHDCA	Allergic rhinitis	CA08.0	Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[59]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[60]
PMID28870136-Compound-48	DMPIM9L	N. A.	N. A.	Patented	[57]
LTC4	DM702WR	Discovery agent	N.A.	Investigative	[9]
LTE4	DMCPB0Q	Discovery agent	N.A.	Investigative	[61]
BAYu9773	DMXQ14V	Discovery agent	N.A.	Investigative	[9]
CGP-57698	DMYZ72J	Discovery agent	N.A.	Investigative	[9]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[46]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[62]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[49]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[63]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[50]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[48]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[64]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[48]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[62]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[65]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[66]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[67]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[67]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[68]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[66]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[67]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[69]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[66]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[8]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[66]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[70]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[7]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[76]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[77]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[78]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[79]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[80]
Selenium	DM25CGV	N. A.	N. A.	Approved	[81]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[82]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[83]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[7]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[7]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[7]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[7]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[84]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[10]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[85]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[86]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[87]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[88]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[89]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[90]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[91]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[92]

Drug(s) Affected By Endothelin-1 (EDN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[93]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[95]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[72]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[98]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[99]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[100]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[101]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[102]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[103]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[104]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[106]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[107]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[108]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[109]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[110]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[77]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[79]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[111]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]

Drug(s) Affected By Eosinophil cationic protein (RNASE3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[112]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[113]
Budesonide	DMJIBAW	Allergic rhinitis	CA08.0	Approved	[114]
Diphenylpyraline	DMW4X37	Allergic rhinitis	CA08.0	Approved	[115]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[116]
Beclomethasone dipropionate	DM5NW1E	Allergic rhinitis	CA08.0	Phase 4	[117]
PHENCYCLIDINE	DMQBEYX	Discovery agent	N.A.	Investigative	[118]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[119]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[120]
Methysergide	DM1EF73	Migraine	8A80	Approved	[69]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[121]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[69]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[123]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[124]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[125]

Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[7]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[7]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[7]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[7]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[127]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[7]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[128]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[129]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[130]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[131]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[132]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[133]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[134]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[135]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[137]

Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[138]
Selenium	DM25CGV	N. A.	N. A.	Approved	[81]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[139]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[140]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[7]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[7]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[7]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[7]

Drug(s) Affected By Interleukin-24 (IL24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[141]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[7]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[77]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[7]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[142]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[7]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[143]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[145]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[146]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[147]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[148]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[149]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[150]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[151]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[109]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[7]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[7]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[7]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[7]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[7]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[7]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[152]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[153]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[7]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[7]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[154]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[155]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene CysLT1 receptor (CYSLTR1)	TTGKOY9	CLTR1_HUMAN	Antagonist	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[4]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[5]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[7]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[8]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[7]
Cysteinyl leukotriene receptor 1 (CYSLTR1)	OT904HBN	CLTR1_HUMAN	Protein Interaction/Cellular Processes	[9]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[7]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[4]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Gene/Protein Processing	[11]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3322).
• [2] Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
• [3] Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012 May;68(5):681-8.
• [4] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [5] Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
• [6] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [7] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [8] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [9] A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9.
• [10] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [11] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [12] Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
• [13] Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
• [14] Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
• [15] Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
• [16] The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
• [17] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [18] Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
• [19] Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
• [20] In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
• [21] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [22] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [23] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [24] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [25] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [26] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [27] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [28] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [29] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [30] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [31] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [32] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [33] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [34] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [35] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [36] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [37] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [38] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [39] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [40] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [41] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [42] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [43] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [44] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [45] Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
• [46] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [47] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [48] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [49] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [50] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [51] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [52] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [53] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [54] Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
• [55] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [56] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [57] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [58] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [59] Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol. 2007 Nov;27(6):613-9. doi: 10.1007/s10875-007-9115-x. Epub 2007 Jul 20.
• [60] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [61] Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. Eur J Pharmacol. 1993 Feb 15;244(3):239-50. doi: 10.1016/0922-4106(93)90149-4.
• [62] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [63] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [64] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [65] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [66] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [67] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [68] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [69] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [70] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [71] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [72] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [73] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [74] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [75] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [76] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [77] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [78] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [79] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [80] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [81] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [82] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [83] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [84] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [85] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [86] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [87] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [88] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [89] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [90] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [91] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [92] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [93] ?-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts. Eur J Pharmacol. 2012 Sep 15;691(1-3):218-24. doi: 10.1016/j.ejphar.2012.07.002. Epub 2012 Jul 13.
• [94] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [95] Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001 Nov-Dec;10(6):311-5. doi: 10.1016/s1054-8807(01)00095-3.
• [96] [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;39(1):72-5.
• [97] Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc Nutr Soc. 2008 Feb;67(1):42-7.
• [98] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [99] Nucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment. Toxicol Sci. 2013 Aug;134(2):323-34. doi: 10.1093/toxsci/kft105. Epub 2013 May 2.
• [100] Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
• [101] Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. doi: 10.1155/2008/305087. Epub 2008 Dec 1.
• [102] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [103] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [104] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [105] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [106] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [107] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [108] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [109] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [110] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [111] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [112] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [113] Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: preliminary study in mild and moderate asthma in Trinidad, West Indies. Int J Clin Pharmacol Res. 2003;23(2-3):69-74.
• [114] Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology. 2004 Nov;9(4):514-20. doi: 10.1111/j.1440-1843.2004.00631.x.
• [115] Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics. Eur Respir J. 1999 Oct;14(4):915-22. doi: 10.1034/j.1399-3003.1999.14d31.x.
• [116] Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1156-60. doi: 10.1164/ajrccm/146.5_Pt_1.1156.
• [117] Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics. J Investig Allergol Clin Immunol. 1999 Jul-Aug;9(4):241-7.
• [118] Differential response of Mono Mac 6, BEAS-2B, and Jurkat cells to indoor dust. Environ Health Perspect. 2007 Sep;115(9):1325-32.
• [119] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [120] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [121] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [122] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [123] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [124] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [125] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [126] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [127] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [128] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [129] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [130] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [131] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [132] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [133] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [134] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [135] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [136] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [137] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [138] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [139] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [140] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [141] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [142] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [143] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [144] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [145] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [146] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [147] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [148] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [149] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [150] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [151] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [152] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [153] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [154] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [155] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.